Indeed, the results are positive enough that one leading pain expert in the US argues the Food and Drug Administration (FDA) should only license abuse resistant painkillers.

FORBES: Is The Era Of OxyContin Abuse Over?

The issues relating to Celebrex and Bextra will come to a head between February 16 and February 18, when the U.S. Food and Drug Administration will host an advisory panel to evaluate the risks of many widely used painkillers.

FORBES: Pfizer's Celebrex Risk Gets Worse